Ascendiant Capital maintains RenovoRx at Buy, raises price target to $15 from $14.50

Ascendiant Capital kept its Buy rating on RenovoRx and increased its price target to $15 from $14.50, a 3.4% rise. This implies a 1227.4% upside from the Nov 6 close of $1.13.

Original reporting
Published Nov 9, 2026, 8:59 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 9, 2026, 9:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Ascendiant Capital maintains RenovoRx at Buy, raises price target to $15 from $14.50 — source image
Decision brief

The 30-second read

Med
01

Why it matters

Analyst upgrade may trigger short‑term price rally but long‑term performance hinges on trial outcomes.

02

Market read

The price target raise is a modest catalyst for RNVR, offering a short‑term trade idea.

03

What to watch

Potential dilution from future financing rounds not addressed.

Relevance 5/10Novelty 5/10Timing: today

Background

RenovoRx is a clinical‑stage biotech focused on rare disease therapies.

Market effects

May lift sentiment in the biotech/clinical‑stage sector.

Limited to US biotech investors.

Minimal global impact.

Counterpoint

Target raise could be premature if upcoming trial data disappoints.

Key entities

  • RenovoRx Inc.

    Biotech firm receiving a price target increase.

  • Ascendiant Capital

    Research firm that raised the price target.

Related articles

$RNXTMed

RenovoRx Inc (RNXT) (Q3 2026) Earnings Call Highlights: Record Revenue, Expanding

RenovoRx Inc (RNXT) reported Q3 2026 record revenue of $1.07M, up 17% sequentially. CEO Sean Bagai discussed potential impacts of Razin-Q approval on pancreatic cancer treatment and commercialization plans. The company has 26 active commercial centers, with a target of 36 by year-end. Phase III TIGER-PACT trial data is expected in H2 2027. Gross margin was 82%, and cash position is $10.4M. Full-year 2026 revenue guidance remains $3.75M-$4.25M.

$RNXTMed

RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel…

RenovoRx, Inc. (RNXT) filed an SEC Form 8-K — Results of Operations and Financial Condition. RenovoRx Reports Record Third Quarter 2026 Revenue Exceeding $1 Million Active Commercial Cancer Center Customers Increased to 26 and Total Commercial Funnel Grows to More Than 65 Centers Maintains 2026 Annual Revenue Guidance of $3.75M to $4.25M First Physician-Driven Expansion

$RNXTMedAI 8/10

RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP Trial

RenovoRx (Nasdaq: RNXT) announced the first patient has enrolled in the PRISM-TAMP trial, evaluating its TAMP platform for borderline resectable pancreatic cancer. The trial, sponsored by the University of Vermont, aims to assess tumor regression and safety. RenovoRx reported $1.1M in 2025 RenovoCath sales and $909K in Q2 2026. The company expects topline data from its Phase III TIGeR-PaC trial in late 2027.

$RNXTMedAI 8/10

RenovoRx Announces Peer-Reviewed Publication Highlighting the TAMP™ Platform's Potential to Improve Chemotherapeutic Delivery for Locally Advanced Pancreatic Cancer

RenovoRx (Nasdaq: RNXT) announced a peer-reviewed publication in Case Reports in Oncology. The study, led by researchers at Hackensack Meridian Health, showed promising results for two locally advanced pancreatic cancer patients treated with the company's TAMP platform and RenovoCath device. The patients experienced tumor responses and reductions in CA 19-9 markers.